As the profiling studies showed an increase in expression of both PD-L1 and CTLA−4 within the TME in response to combination therapy, we next investigated whether targeting these immune checkpoint pathways could further enhance long-term tumor control. The gene discussed is CTLA4; the disease is neoplasm.